Syndax Pharmaceuticals (NASDAQ:SNDX) Given New $47.00 Price Target at HC Wainwright

Syndax Pharmaceuticals (NASDAQ:SNDX) had its price target boosted by HC Wainwright from $45.00 to $47.00 in a research note issued to investors on Wednesday morning,Benzinga reports. The firm currently has a buy rating on the stock. HC Wainwright also issued estimates for Syndax Pharmaceuticals’ Q4 2024 earnings at ($1.20) EPS, FY2024 earnings at ($3.83) EPS, FY2025 earnings at ($3.75) EPS and FY2026 earnings at ($2.96) EPS.

Several other research analysts have also commented on SNDX. Stifel Nicolaus increased their price target on shares of Syndax Pharmaceuticals from $40.00 to $41.00 and gave the stock a “buy” rating in a research note on Monday, October 14th. JPMorgan Chase & Co. dropped their price target on shares of Syndax Pharmaceuticals from $34.00 to $33.00 and set an “overweight” rating on the stock in a research note on Tuesday, August 6th. Bank of America raised their target price on shares of Syndax Pharmaceuticals from $30.00 to $31.00 and gave the company a “buy” rating in a research note on Thursday, August 15th. Citigroup raised their target price on shares of Syndax Pharmaceuticals from $30.00 to $34.00 and gave the company a “buy” rating in a research note on Friday, August 16th. Finally, UBS Group started coverage on shares of Syndax Pharmaceuticals in a research note on Thursday, October 24th. They issued a “buy” rating and a $37.00 target price on the stock. Two investment analysts have rated the stock with a hold rating and ten have issued a buy rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $35.82.

Syndax Pharmaceuticals Stock Up 1.3 %

SNDX stock opened at $21.81 on Wednesday. Syndax Pharmaceuticals has a 12-month low of $13.14 and a 12-month high of $25.34. The company has a market cap of $1.86 billion, a price-to-earnings ratio of -6.01 and a beta of 0.92. The company has a 50 day moving average of $19.11 and a two-hundred day moving average of $20.33.

Syndax Pharmaceuticals (NASDAQ:SNDX) last announced its quarterly earnings results on Tuesday, November 5th. The company reported ($0.98) EPS for the quarter, topping the consensus estimate of ($1.13) by $0.15. The business had revenue of $12.50 million for the quarter, compared to analyst estimates of $9.16 million. During the same quarter last year, the company earned ($0.73) EPS. On average, research analysts anticipate that Syndax Pharmaceuticals will post -3.66 EPS for the current year.

Institutional Trading of Syndax Pharmaceuticals

Several hedge funds and other institutional investors have recently bought and sold shares of SNDX. Nvwm LLC acquired a new stake in Syndax Pharmaceuticals in the 1st quarter worth $1,022,000. Swiss National Bank lifted its holdings in shares of Syndax Pharmaceuticals by 5.8% during the 1st quarter. Swiss National Bank now owns 150,600 shares of the company’s stock worth $3,584,000 after acquiring an additional 8,200 shares during the period. Susquehanna Fundamental Investments LLC bought a new position in shares of Syndax Pharmaceuticals during the 1st quarter worth about $2,614,000. Sei Investments Co. lifted its holdings in shares of Syndax Pharmaceuticals by 2.5% during the 1st quarter. Sei Investments Co. now owns 40,463 shares of the company’s stock worth $963,000 after acquiring an additional 991 shares during the period. Finally, ProShare Advisors LLC lifted its holdings in shares of Syndax Pharmaceuticals by 29.6% during the 1st quarter. ProShare Advisors LLC now owns 20,112 shares of the company’s stock worth $479,000 after acquiring an additional 4,599 shares during the period.

About Syndax Pharmaceuticals

Syndax Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF).